Creative Medical Technology Holdings EBIT

The latest EBIT for CELZ is $-3.2M as of June 2026. That compares with $-5.8M in the prior-year period — up 44.2% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Creative Medical Technology Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CELZ's EBIT moved from $-5.8M to $-3.2M — a 44.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Creative Medical Technology Holdings's operating scale or balance-sheet position.

Against its sector companies, CELZ currently prints $-3.2M for EBIT, while the sector average sits near $-63M. That is roughly 94.8% above the sector mean. Large gaps often invite a closer look at Creative Medical Technology Holdings's growth, margins, and balance sheet.

A EBIT figure of $-3.2M for CELZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting CELZ's EBIT ($-3.2M), review year-over-year change from $-5.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.